Prevalence of five pharmacologically most important CYP2C9 and CYP2C19 allelic variants in the population from the Republic of Srpska in Bosnia and Herzegovina
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Sim SC, Kacevska M, Ingelman-Sundberg M. Pharmacogenomics of drug-metabolizing enzymes: A recent update on clinical implications and endogenous effects. Pharmacogenomics J 2013;13:1–11. doi: 10.1038/tpj.2012.45SimSCKacevskaMIngelman-SundbergMPharmacogenomics of drug-metabolizing enzymes: A recent update on clinical implications and endogenous effects20131311110.1038/tpj.2012.4523089672Open DOISearch in Google Scholar
Mustafa G, Nandekar PP, Bruce NJ, Wade RC. Differing membrane interactions of two highly similar drug-metabolizing cytochrome P450 isoforms: CYP 2C9 and CYP 2C19. Int J Mol Sci 2019;20:4328. doi: 10.3390/ijms20184328MustafaGNandekarPPBruceNJWadeRCDiffering membrane interactions of two highly similar drug-metabolizing cytochrome P450 isoforms: CYP 2C9 and CYP 2C19201920432810.3390/ijms20184328677066131487853Open DOISearch in Google Scholar
Sim SC, Altman RB, Ingelman-Sundberg M. Databases in the area of pharmacogenetics. Hum Mutat 2011;32:526–31. doi: 10.1002/humu.21454SimSCAltmanRBIngelman-SundbergMDatabases in the area of pharmacogenetics2011325263110.1002/humu.21454335202721309040Open DOISearch in Google Scholar
Raunio H. Modeling of interactions between xenobiotics and cytochrome P450 (CYP) enzymes. Front Pharmacol 2015;6:123. doi: 10.3389/fphar.2015.00123RaunioHModeling of interactions between xenobiotics and cytochrome P450 (CYP) enzymes2015612310.3389/fphar.2015.00123446416926124721Open DOISearch in Google Scholar
Subramanian M, Agrawal V, Sandee D, Tam HK, Miller WL, Tracy TS. Effect of P450 oxidoreductase variants on the metabolism of model substrates mediated by CYP2C9.1, CYP2C9.2, and CYP2C9.3. Pharmacogenet Genomics 2012;22:590–7. doi: 10.1097/FPC.0b013e3283544062SubramanianMAgrawalVSandeeDTamHKMillerWLTracyTSEffect of P450 oxidoreductase variants on the metabolism of model substrates mediated by CYP2C9.1, CYP2C9.2, and CYP2C9.3201222590710.1097/FPC.0b013e328354406222547083Open DOISearch in Google Scholar
Wu AHB. Drug metabolizing enzyme activities versus genetic variances for drug of clinical pharmacogenomic relevance. Clin Proteomics 2011;8:12. doi: 10.1186/15590275-8-12WuAHBDrug metabolizing enzyme activities versus genetic variances for drug of clinical pharmacogenomic relevance201181210.1186/15590275-8-12Open DOISearch in Google Scholar
Shirasaka Y, Chaudhry AS, McDonald M, Prasad B, Wong T, Calamia JC, Fohner A, Thornton TA, Isoherranen N, Unadkat JD, Rettie AE, Schuetz EG, Thummel KE. Interindividual variability of CYP2C19-catalyzed drug metabolism due to differences in gene diplotypes and cytochrome P450 oxidoreductase content. Pharmacogenomics J 2016;16:375–87. doi: 10.1038/tpj.2015.58ShirasakaYChaudhryASMcDonaldMPrasadBWongTCalamiaJCFohnerAThorntonTAIsoherranenNUnadkatJDRettieAESchuetzEGThummelKEInterindividual variability of CYP2C19-catalyzed drug metabolism due to differences in gene diplotypes and cytochrome P450 oxidoreductase content2016163758710.1038/tpj.2015.58477543626323597Open DOISearch in Google Scholar
Ganoci L, Božina T, Mirošević Skvrce N, Lovrić M, Mas P, Božina N. Genetic polymorphisms of cytochrome P450 enzymes: CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 in the Croatian population. Drug Metab Pers Ther 2017;32:11–21. doi: 10.1515/dmpt-2016-0024GanociLBožinaTMiroševićSkvrce NLovrićMMasPBožinaNGenetic polymorphisms of cytochrome P450 enzymes: CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 in the Croatian population201732112110.1515/dmpt-2016-002428272018Open DOISearch in Google Scholar
Theken KN, Lee CR, Gong L, Caudle KE, Formea CM, Gaedigk A, Klein TE, Agúndez JAG, Grosser T. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2C9 and nonsteroidal anti-inflammatory drugs. Clin Pharmacol Ther 2020;108:191–200. doi: 10.1002/cpt.1830ThekenKNLeeCRGongLCaudleKEFormeaCMGaedigkAKleinTEAgúndezJAGGrosserTClinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2C9 and nonsteroidal anti-inflammatory drugs202010819120010.1002/cpt.1830808088232189324Open DOISearch in Google Scholar
Kirchheiner J, Brockmöller J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther 2005;77:1–16. doi: 10.1016/j.clpt.2004.08.009KirchheinerJBrockmöllerJClinical consequences of cytochrome P450 2C9 polymorphisms20057711610.1016/j.clpt.2004.08.00915637526Open DOISearch in Google Scholar
Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 2007;116:496–526. doi: 10.1016/j.pharmthera.2007.09.004Ingelman-SundbergMSimSCGomezARodriguez-AntonaCInfluence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects200711649652610.1016/j.pharmthera.2007.09.00418001838Open DOISearch in Google Scholar
Šupe S, Poljaković Z, Božina T, Ljevak J, Macolić Šarinić V, Božina N. Clinical application of genotype-guided dosing of warfarin in patients with acute stroke. Arch Med Res 2015;46:265–73. doi: 10.1016/j.arcmed.2015.05.001ŠupeSPoljakovićZBožinaTLjevakJMacolićŠarinić VBožinaNClinical application of genotype-guided dosing of warfarin in patients with acute stroke2015462657310.1016/j.arcmed.2015.05.00125989350Open DOISearch in Google Scholar
Shendre A, Dillon C, Limdi NA. Pharmacogenetics of warfarin dosing in patients of African and European ancestry. Pharmacogenomics 2018;19:1357–71. doi: 10.2217/pgs-2018-0146ShendreADillonCLimdiNAPharmacogenetics of warfarin dosing in patients of African and European ancestry20181913577110.2217/pgs-2018-0146656276430345882Open DOISearch in Google Scholar
El Rouby N, Lima JJ, Johnson JA. Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine. Expert Opin Drug Metab Toxicol 2018;14:447–60. doi: 10.1080/17425255.2018.1461835ElRouby NLimaJJJohnsonJAProton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine2018144476010.1080/17425255.2018.1461835594215429620484Open DOISearch in Google Scholar
Janha RE, Worwui A, Linton KJ, Shaheen SO, Sisay-Joof F, Walton RT. Inactive alleles of cytochrome P450 2C19 may be positively selected in human evolution. BMC Evol Biol 2014;14:71. doi: 10.1186/1471-2148-14-71JanhaREWorwuiALintonKJShaheenSOSisay-JoofFWaltonRTInactive alleles of cytochrome P450 2C19 may be positively selected in human evolution2014147110.1186/1471-2148-14-71403653224690327Open DOISearch in Google Scholar
Dehbozorgi M, Kamalidehghan B, Hosseini I, Dehghanfard Z, Sangtarash MH, Firoozi M, Ahmadipour F, Meng GY, Houshmand M. Prevalence of the CYP2C19*2 (681 G>A), *3 (636 G>A) and *17 (-806 C>T) alleles among an Iranian population of different ethnicities. Mol Med Rep 2018;17:4195–202. doi: 10.3892/mmr.2018.8377DehbozorgiMKamalidehghanBHosseiniIDehghanfardZSangtarashMHFirooziMAhmadipourFMengGYHoushmandMPrevalence of the CYP2C19*2 (681 G>A), *3 (636 G>A) and *17 (-806 C>T) alleles among an Iranian population of different ethnicities201817419520210.3892/mmr.2018.8377580219029328413Open DOISearch in Google Scholar
Jakovski K, Nestorovska AK, Labacevski N, Dimovski AJ. Characterization of the most common CYP2C9 and CYP2C19 allelic variants in the population from the Republic of Macedonia. Pharmazie 2013;68:893–8. PMID: 24380239JakovskiKNestorovskaAKLabacevskiNDimovskiAJCharacterization of the most common CYP2C9 and CYP2C19 allelic variants in the population from the Republic of Macedonia2013688938PMID: 24380239Search in Google Scholar
Hicks JK, Sangkuhl K, Swen JJ, Ellingrod VL, Müller DJ, Shimoda K, Bishop JR, Kharasch ED, Skaar TC, Gaedigk A, Dunnenberger HM, Klein TE, Caudle KE, Stingl JC. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther 2017;102:37–44. doi: 10.1002/cpt.597HicksJKSangkuhlKSwenJJEllingrodVLMüllerDJ,ShimodaKBishopJRKharaschEDSkaarTCGaedigkADunnenbergerHMKleinTECaudleKEStinglJCClinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update2017102374410.1002/cpt.597547847927997040Open DOISearch in Google Scholar
Hicks JK, Bishop JR, Sangkuhl K, Muller DJ, Ji Y, Leckband SG, Leeder JS, Graham RL, Chiulli DL, LLerena A, Skaar TC, Scott SA, Stingl JC, Klein TE, Caudle KE, Gaedigk A. Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther 2015;98:127–34. doi: 10.1002/cpt.147HicksJKBishopJRSangkuhlKMullerDJJiYLeckbandSGLeederJSGrahamRLChiulliDLLLerenaA,SkaarTCScottSAStinglJCKleinTECaudleKEGaedigkAClinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors2015981273410.1002/cpt.147451290825974703Open DOISearch in Google Scholar
Burian M, Grösch S, Tegeder I, Geisslinger G. Validation of a new fluorogenic real-time PCR assay for detection of CYP2C9 allelic variants and CYP2C9 allelic distribution in a German population. Br J Clin Pharmacol 2002;54:518–21. doi: 10.1046/j.1365-2125.2002.01693.xBurianMGröschSTegederIGeisslingerGValidation of a new fluorogenic real-time PCR assay for detection of CYP2C9 allelic variants and CYP2C9 allelic distribution in a German population2002545182110.1046/j.1365-2125.2002.01693.x187448012445031Open DOISearch in Google Scholar
Republika Srpska I of S. Population estimates, annual rellease 2013–2019. 2020;158(20):1.Republika Srpska I of SPopulation estimates2020158201Search in Google Scholar
Gaikovitch EA, Cascorbi I, Mrozikiewicz PM, Brockmöller J, Frötschl R, Köpke K, Gerloff T, Chernov JN, Roots I. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. Eur J Clin Pharmacol 2003;59:303–12. doi: 10.1007/s00228-003-0606-2GaikovitchEACascorbiIMrozikiewiczPMBrockmöllerJFrötschlRKöpkeK,GerloffTChernovJNRootsIPolymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population200359303–1210.1007/s00228-003-0606-212879168Open DOISearch in Google Scholar
Dorado P, Berecz R, Norberto MJ, Yasar Ü, Dahl ML, LLerena A. CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers. Eur J Clin Pharmacol 2003;59:221–5. doi: 10.1007/s00228-003-0588-0DoradoPBereczRNorbertoMJYasarÜDahlMLLLerenaACYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers200359221510.1007/s00228-003-0588-012734606Open DOISearch in Google Scholar
Arvanitidis K, Ragia G, Iordanidou M, Kyriaki S, Xanthi A, Tavridou A, Manolopoulos VG. Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population. Fundam Clin Pharmacol 2 0 0 7 ; 2 1 : 4 1 9 – 2 6 . doi: 10.1111/j.1472-8206.2007.00510.xArvanitidisKRagiaGIordanidouMKyriakiSXanthiATavridouAManolopoulosVGGenetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population2 0 0 7 ; 2 1 : 4 1 9 – 2 6 10.1111/j.1472-8206.2007.00510.x17635181Open DOISearch in Google Scholar
Skadrić I, Stojković O. Defining screening panel of functional variants of CYP1A1, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 genes in Serbian population. Int J Legal Med 2019;134:433–9. doi: 10.1007/s00414-019-02234-7SkadrićIStojkovićODefining screening panel of functional variants of CYP1A1, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 genes in Serbian population2019134433910.1007/s00414-019-02234-731858263Open DOISearch in Google Scholar
Herman D, Dolžan V, Breskvar K. Genetic polymorphism of cytochromes P450 2C9 and 2C19 in Slovenian population. Zdr Vestn 2003;72:347–51.HermanDDolžanVBreskvarKGenetic polymorphism of cytochromes P450 2C9 and 2C19 in Slovenian population20037234751Search in Google Scholar
Buzoianu AD, Militaru FC, Vesa ŞC, Trifa AP, Crişan S. The impact of the CYP2C9 and VKORC1 polymorphisms on acenocoumarol dose requirements in a Romanian population. Blood Cells Mol Dis 2013;50:166–70. doi: 10.1016/j.bcmd.2012.10.010BuzoianuADMilitaruFCVesaŞCTrifaAPCrişanSThe impact of the CYP2C9 and VKORC1 polymorphisms on acenocoumarol dose requirements in a Romanian population2013501667010.1016/j.bcmd.2012.10.01023159639Open DOISearch in Google Scholar
Sistonen J, Fuselli S, Palo JU, Chauhan N, Padh H, Sajantila A. Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales. Pharmacogenet Genomics 2009;19:170–9. doi: 10.1097/ FPC.0b013e32831ebb30SistonenJFuselliSPaloJUChauhanNPadhHSajantilaAPharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales200919170910.1097/FPC.0b013e32831ebb3019151603Open DOISearch in Google Scholar
Johnson JA, Caudle KE, Gong L, Whirl-Carrillo M, Stein CM, Scott SA, Lee MT, Gage BF, Kimmel SE, Perera MA, Anderson JL, Pirmohamed M, Klein TE, Limdi NA, Cavallari LH, Wadelius M. Clinical pharmacogenetics implementation consortium (CPIC) guideline for pharmacogenetics-guided warfarin dosing: 2017 update. Clin Pharmacol Ther 2017; 102:397–404. doi: 10.1002/cpt.668JohnsonJACaudleKEGongLWhirl-CarrilloMSteinCMScottSALeeMTGageBFKimmelSEPereraMAAndersonJLPirmohamedMKleinTELimdiNACavallariLHWadeliusMClinical pharmacogenetics implementation consortium (CPIC) guideline for pharmacogenetics-guided warfarin dosing: 2017 update201710239740410.1002/cpt.668554694728198005Open DOISearch in Google Scholar
Krasniqi V, Dimovski A, Bytyqi HQ, Eftimov A, Šimičevic L, Božina N. Genetic polymorphisms of CYP2C9, CYP2C19, and CYP3A5 in Kosovar population. Arh Hig Rada Toksikol 2017;68:180–4. doi: 10.1515/aiht-2017-68-2998KrasniqiVDimovskiABytyqiHQEftimovAŠimičevicLBožinaNGenetic polymorphisms of CYP2C9, CYP2C19, and CYP3A5 in Kosovar population201768180410.1515/aiht-2017-68-299828976882Open DOISearch in Google Scholar
Bathum L, Andersen-Ranberg K, Boldsen J, Brøsen K, Jeune B. Genotypes for the cytochrome p450 enzymes CYP2D6 and CYP2C19 in human longevity. Role of CYP2D6 and CYP2C19 in longevity. Eur J Clin Pharmacol 1998;54:427–30. doi: 10.1007/s002280050487BathumLAndersen-RanbergKBoldsenJBrøsenKJeuneBGenotypes for the cytochrome p450 enzymes CYP2D6 and CYP2C19 in human longevity199854427–3010.1007/s0022800504879754988Open DOISearch in Google Scholar
Jurima-Romet M, Goldstein JA, LeBelle M, Aubin RA, Foster BC, Walop W, Rode A. CYP2C19 genotyping and associated mephenytoin hydroxylation polymorphism in a Canadian Inuit population. Pharmacogenetics 1996;6:329–39. doi: 10.1097/00008571-199608000-00006Jurima-RometMGoldsteinJALeBelleMAubinRAFosterBCWalopWRodeACYP2C19 genotyping and associated mephenytoin hydroxylation polymorphism in a Canadian Inuit population19966329–3910.1097/00008571-199608000-000068873219Open DOISearch in Google Scholar
Brockmöller J, Rost K, Gross D, Schenkel A, Roots I. Phenotyping of CYP2C19 with enantiospecific HPLC quantification of R and S mephenytoin and comparison with the intron4/exon5 G >A splice site mutation. Pharmacogenetics 1995;5:80–8. doi: 10.1097/00008571-199504000-00004BrockmöllerJRostKGrossDSchenkelARootsIPhenotyping of CYP2C19 with enantiospecific HPLC quantification of R and S mephenytoin and comparison with the intron4/exon5 G >A splice site mutation1995580810.1097/00008571-199504000-000047663532Open DOISearch in Google Scholar
Kurzawski M, Gawrońska-Szklarz B, Wrześniewska J, Siuda A, Starzyńska T, Droździk M. Effect of CYP2C19*17 gene variant on Helicobacter pylori eradication in peptic ulcer patients. Eur J Clin Pharmacol 2006;62:877–80. doi: 10.1007/s00228-006-0183-2KurzawskiMGawrońska-SzklarzBWrześniewskaJSiudaAStarzyńskaTDroździkMEffect of CYP2C19*17 gene variant on Helicobacter pylori eradication in peptic ulcer patients2006628778010.1007/s00228-006-0183-216912869Open DOISearch in Google Scholar
Hoskins JM, Shenfield GM, Gross AS. Relationship between proguanil metabolic ratio and CYP2C19 genotype in a Caucasian population. Br J Clin Pharmacol 1998;45:499–504. doi: 10.1046/j.1365-2125.1998.00807.xHoskinsJMShenfieldGMGrossASRelationship between proguanil metabolic ratio and CYP2C19 genotype in a Caucasian population199845499–50410.1046/j.1365-2125.1998.00807.x18736909833604Open DOISearch in Google Scholar
Ašić A, Salazar R, Storm N, Doğan S, Höppner W, Marjanović D, Primorac D. Population study of thrombophilic markers and pharmacogenetic markers of warfarin prevalence in Bosnia and Herzegovina. Croat Med J 2019;60:212–20. doi: 10.3325/cmj.2019.60.212AšićASalazarRStormNDoğanSHöppnerWMarjanovićDPrimoracDPopulation study of thrombophilic markers and pharmacogenetic markers of warfarin prevalence in Bosnia and Herzegovina2019602122010.3325/cmj.2019.60.212Open DOISearch in Google Scholar
Semiz S, Dujić T, Ostanek B, Prnjavorac B, Bego T, Malenica M. Analysis of CYP2C9*2, CYP2C19*2, and CYP2D6*4 polymorphisms in patients with type 2 diabetes mellitus. Bosn J BASIC Med Sci 2010;10:287–91. doi: 10.17305/bjbms.2010.2662SemizSDujićTOstanekBPrnjavoracBBegoTMalenicaMAnalysis of CYP2C9*2, CYP2C19*2, and CYP2D6*4 polymorphisms in patients with type 2 diabetes mellitus2010102879110.17305/bjbms.2010.2662548903621108610Open DOISearch in Google Scholar
Božina N, Granić P, Lalić Z, Tramišak I, Lovrić M, Stavljenić-Rukavina A. Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population. Croat Med J 2003;44:425–8. PMID: 12950145BožinaNGranićPLalićZTramišakILovrićMStavljenić-RukavinaAGenetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population2003444258PMID: 12950145Search in Google Scholar
Herman D, Locatelli I, Grabnar I, Peternel P, Stegnar M, Mrhar A, Breskvar K, Dolzan V. Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose. Pharmacogenomics J 2005;5:193–202. doi: 10.1038/sj.tpj.6500308HermanDLocatelliIGrabnarIPeternelPStegnarMMrharABreskvarKDolzanVInfluence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose2005519320210.1038/sj.tpj.650030815824753Open DOISearch in Google Scholar
Arici M, Özhan G. CYP2C9, CYPC19 and CYP2D6 gene profiles and gene susceptibility to drug response and toxicity in Turkish population. Saudi Pharm J 2017;25:376–80. doi: 10.1016/j.jsps.2016.09.003AriciMÖzhanGCYP2C9, CYPC19 and CYP2D6 gene profiles and gene susceptibility to drug response and toxicity in Turkish population2017253768010.1016/j.jsps.2016.09.003535709828344492Open DOISearch in Google Scholar
Scordo MG, Caputi AP, D’Arrigo C, Fava G, Spina E. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. Pharmacol Res 2004;50:195–200. doi: 10.1016/j.phrs.2004.01.004ScordoMGCaputiAPD’ArrigoC,FavaGSpinaEAllele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population20045019520010.1016/j.phrs.2004.01.00415177309Open DOISearch in Google Scholar